We have previously reported a functional role associated with hepatitis C virus (HCV) E1 glycoprotein using vesicular stomatitis virus (VSV)/HCV pseudotype. In this study, we have investigated the role of glycosylation upon intracellular transport of chimeric E1-G, and in infectivity of the pseudotyped virus. Interestingly, surface expressed E1-G exhibited sensitivity to Endoglycosidase H (Endo H) treatment, which was similar to full-length E1, suggesting that additional complex oligosaccharides were not added while E1-G was in transit from the endoplasmic reticulum (ER) to the mammalian cell surface. As a next step, each of the four potential N-linked glycosylation sites located at amino acid position 196, 209, 234, or 305 of the E1 ectodomain were mutated separately (asparagine ! glutamine), or in some combination. FACS analysis suggested that mutation(s) of the glycosylation sites affect the translocation of E1-G to the cell surface to different extents, with no single site being particularly essential. VSV pseudotype virus generated from glycosylation mutants exhibited a decrease in titer with an increasing number of mutations at the glycosylation sites on chimeric E1-G. In a separate experiment, N-glycosidase F treatment of pseudotype generated from the already synthesized E1-G or its mutants decreased virus titer by approximately 35%, and the neutralization activity of patient sera was not significantly altered with N-glycosidase F-treated pseudotype virus. Taken together, our results suggested that E1-G does not add complex sugar moieties during transport to the cell surface and retain the glycosylation profile of its parental E1 sequence. Additionally, the removal of glycans from the E1-G reduced, but does not completely impair, virus infectivity.
Introduction
Hepatitis C virus (HCV) causes a spectrum of disease ranging from an asymptomatic carrier state to end-stage liver disease, which includes cirrhosis and hepatocellular carcinoma (DiBisceglie et al., 1998; Hayashi et al., 1999; Jeffers, 2000; Saito et al., 1990) . The study of HCV is challenging due to its inefficient replication in cell culture and the lack of a small animal model. HCV genome is a single positive-strand RNA that encodes a polyprotein of approximately 3000 amino acids. The polyprotein is cleaved by both host and viral proteases to generate at least 10 different proteins. The structural proteins of HCV (core, E1, and E2/p7) are processed by host peptidase present in the endoplasmic reticulum (ER) lumen. Immunoelectron microscopic study suggests that the E1 and E2 glycoproteins are located on the virus envelope (Kaito et al., 1994) , and they most likely facilitate virus entry by interacting with host cell surface. During HCV protein synthesis, E1 glycoprotein (approximately 32 kDa) localizes in the cytoplasm and is retained in the ER (Hijikata et al., 1991; Ralston et al., 1993; Spaete et al., 1992) . E1 glycosylation is sensitive to Endo H digestion, further suggesting that this viral glycoprotein is not modified by Golgi (Lanford et al., 1993) . The E1 protein consists of 191 amino acids occupying positions between amino acid residues 192 -383 in the HCV polyprotein. E1 contains five conserved potential glycosylation sites at amino acid positions 196, 209, 234, 305, and 325 ; however, position 325 is not efficiently glycosylated . This viral protein has two hydrophobic domains, located at the internal position between amino acid residues 261 and 291, and at the C-terminal region between amino acid residues 329 and 383 (Takamizawa et al., 1991) . The C-terminal domain has the retention signal in the ER membrane, while the internal domain is involved in binding with capsid protein Ma et al., 2002) , and may have membrane-active properties (Ciccaglione et al., 2001) .
N-linked glycosylation of viral polypeptides are important for a variety of biological and immunological functions (Hansen et al., 1990; Helenius, 1994; Varki, 1993) . Glycosylation of proteins also help in the formation and maintenance of native protein conformation, and protect the protein from proteolytic degradation (Ellgaard et al., 1999; Means and Desrosiers, 2000; Trombetta and Helenius, 1998) . However, the blocking of N-linked glycosylation sites has suggested that some proteins are not affected, whereas others are degraded or fail to reach their correct cellular destination (Machamer et al., 1985; Olden et al., 1982; Sodora et al., 1989) . Little is known about the relative contribution of the protein and carbohydrate to the various activities of HCV envelope glycoproteins. We have previously shown that concanavalin A plant lectin interacts with pseudotype virus expressing the ectodomain of HCV E1 glycoprotein, while mannose-binding protein (a C-type mammalian lectin) did not (Meyer et al., 2000) . Recent studies from other investigators suggest that pseudotype expressing chimeric E1 glycoprotein binds efficiently to DC-SIGN and DC-SIGNR expressed on cells, but not to other C-type lectins (Lozach et al., 2003; Pohlmann et al., 2003) .
The lack of an efficient in vitro system for the propagation of HCV makes it difficult to identify cell surface attachment factors or virus receptors. We have developed a pseudotype virus system to understand the role of HCV envelope glycoproteins in the initiation of viral infection (Lagging et al., 1998) . A temperature-sensitive mutant of vesicular stomatitis virus (VSVts045) was used as the core virus for generation of pseudotype. This VSVts045 has a single amino acid mutation on the surface glycoprotein G. At permissive temperature (32 jC), VSVts045 assemble normally and display infectivity. In contrast, when VSVts045 is grown at a nonpermissive temperature (40.5 jC), the G glycoprotein undergoes a conformational change, which leads to its retention in the endoplasmic reticulum (Doms et al., 1993) .
As a result, VSVts045 is unable to assemble its spike glycoprotein G for virus morphogenesis. We exploited this unique property of VSVts045 to generate VSV/HCV pseudotype virus. Pseudotype expressing chimeric E1-G or E2-G glycoprotein displayed infectivity at permissive temperature (32 jC), suggesting an individual role for each in cell surface interaction for virus entry. Sera derived from chimpanzees immunized with homologous HCV glycoproteins neutralized E1 or E2 pseudotype virus infectivity (Lagging et al., 1998) . We also used the pseudotype virus as a surrogate model in determining virus neutralization activity of HCVinfected patient sera. Pseudotype virus neutralizing activity of patient sera did not exhibit a correlation with the genotype of the infecting HCV, suggesting that neutralizing epitope(s) may be shared among HCV genotypes . Only a limited number of studies have been directed to mutation(s) of the glycosylation sites to determine which specific N-linked glycans are critical for envelope protein function. We extended our investigation in determining whether E1-G glycoprotein processing is affected as a result of translocation from the ER to the cell surface, and how the carbohydrate portion on E1-G influences its functional properties.
Results
Transport of E1-G chimeric glycoprotein to mammalian cell surface and Endoglycosidase H sensitivity HCV E1 glycoprotein contains an ER retention signal in its transmembrane (TM) domain. The removal of the ER retention sequence allows secretion of E1 as a recombinant protein in mammalian cell culture medium. We generated a chimeric E1 glycoprotein construct (E1-G) by replacing its TM domain with sequences encoding VSV G TM domain and cytoplasmic tail for translocation of E1 on cell surface (Lagging et al., 1998) . Confocal microscopy using a monoclonal antibody to E1 glycoprotein (A4), anti-calnexin antibody as an ER marker, or anti-giantin antibody as a Golgi marker suggested that chimeric E1-G does transit from the ER through the Golgi complex (Fig. 1, panel A) . To determine whether the oligosaccharides present on E1-G Fig. 1 . (Panel A) E1-G chimeric glycoprotein translocates onto cell surface through Golgi complex. HeLa cells were infected with recombinant vvT7 and transfected with E1-G plasmid DNA. Cells were stained after 18 h with a murine MAb A4 to E1 and rabbit anti-calnexin antibody as an ER marker or rabbit anti-giantin antibody as a Golgi marker. A secondary antibody to murine Ig-FITC conjugate and rabbit Ig-TRITC conjugate were used. Fluorescence images were merged digitally for fine comparison. (Panel B) E1-G chimeric protein is Endo H sensitive. HeLa cells were infected with recombinant vvT7 and transfected with plasmid DNA encoding chimeric E1-G, full-length E1, or pcDNA3 vector as a negative control. After 18 h of transfection, cells were labeled with 35 S-cysteine/methionine for 2 h. Cell lysates were immunoprecipitated with a MAb A4 to E1 and left as untreated control or treated with Endo H. Samples were analyzed by SDS-12% PAGE under reducing conditions. Arrows on the left indicate positions of protein bands from undigested or Endo H digested (marked by *) E1-G or E1. The positions of protein molecular weight markers (Invitrogen) are indicated as kilodaltons on the right. (Panel C) Western blot analysis for Endo H sensitivity of chimeric E1-G. HeLa cells were infected with recombinant vvT7 and transfected with plasmid DNA encoding chimeric E1-G, full-length E1, or pcDNA3 vector as a negative control. After 18 h of transfection, cell lysates were immunoprecipitated with a MAb to E1 (Austral Biologicals). Immunoprecipitates were digested with Endo H or left untreated as a control. Samples were analyzed by SDS-12% PAGE, transferred to nitrocellulose membrane, and E1 protein was detected using MAb A4, followed by anti-mouse immunoglobulin peroxidase conjugate. The peroxidase signal was visualized by chemiluminescence. Arrows on the left indicate the positions of protein bands from undigested or Endo H digested (marked by *) E1-G or E1. The positions of protein molecular weight markers (Invitrogen) are indicated as kilodaltons on the right. are modified in the Golgi while being transported to the cell surface, the chimeric glycoprotein was treated with Endoglycosidase H (Endo H), which catalyzes the hydrolysis of N-linked oligomannose and hybrid, but not complex, oligosaccharides. The surface expressed chimeric E1-G displayed Endo H sensitivity similar to ER resident full-length E1 glycoprotein (Fig. 1, panel B (Fig. 1C) . These results indicated that the glycosylation pattern of chimeric E1-G was similar to the full-length E1 glycoprotein containing high mannose oligosaccharides even after translocation from the ER to mammalian cell surface via Golgi complex.
Role of glycosylation sites on protein expression profile of E1-G The E1 glycoprotein (approximately 32 kDa) consists of 191 amino acids encoding from amino acid positions 192 to 383 of the HCV genotype 1a polyprotein sequence. Most of the HCV genotypes have five conserved potential N-glycosylation sites in their E1 sequence (asparagine positions 196, 209, 234, 305, and 325) . However, the site at position 325 (Asn-Trp-Ser-Pro) is not used for the addition of an N-linked glycan. We asked how mutation of a single or multiple glycosylation sites in the E1 sequence may affect molecular size of the chimeric E1-G glycoprotein. To address this question, we replaced the asparagine residues of 196, 209, 234, and 305 with glutamine by oligonucleotide-directed mutagenesis to prevent the addition of N-linked oligosaccharides. Mutations at each of the four amino acid positions were verified by automated DNA sequence analysis. E1-G glycosylation mutants were cloned under the control of a cytomegalovirus early promoter into pcDNA3 mammalian expression vector for transient protein expression in HeLa cells. Analysis of protein expression from the mutated clones were compared with the parental E1-G or vector control by immunoprecipitation, and results suggested a consistent decrease of molecular weight with single or multiple mutations at the E1-G glycosylation sites (Fig. 2) . The chimeric E1-G glycoprotein appeared as an approximately 34.5-kDa polypeptide band. On the other hand, mutation at a single glycosylation site (N 196 ! Q) displayed a major protein band approximately 32 kDa and a minor polypeptide of approximately 29 kDa probably representing partially glycosylated form of this protein. A similar change in molecular weight of the polypeptide band was also observed with single mutations at three other glycosylation sites (data not shown). The other three additive mutants exhibited synthesis of distinct polypeptides of different molecular weights (approximately 29, 25, and 20 kDa) depending on the number of mutations performed on N-glycosylation sites.
Role of glycosylation sites on transport of E1-G chimeric glycoprotein
Transient expression of E1-G mutant glycoprotein on HeLa cell surface was examined by immunofluorescence from unfixed cells. All of the E1-G mutated proteins were recognized by a MAb targeting a linear epitope located between aa 192 and 280 on the polyprotein or by MAb A4 recognizing a linear epitope between amino acids 197 and 207, which corresponds to a domain outside of the N-linked glycosylation sites. Our results suggested a gradual decrease in cell surface expression level of E1-G protein with an increasing number of mutations to the glycosylation sites (Fig. 3, panels A and B) . Translocation of the mutated E1-G to the cell surface was quantitated subsequently by FACS analysis. Approximately 29% of cells displayed cell surface expression of E1-G chimeric glycoprotein by FACS. Similar analyses suggested approximately 12 -20% cell surface expression of E1-G following single mutation at any one of the four glycosylation sites. On the other hand, double mutations at two different amino acids, 196 and 305, decreased E1-G surface expression to approximately 7.5%. Cell surface expression of E1-G was almost undetectable (approximately 3%) when three of the glycosylation sites were mutated simultaneously. Mutations of all four glycosylation sites failed to display any significant signal (approximately 1.5%) by FACS analysis.
To investigate intracellular localization of E1-G or its mutants, we performed confocal microscopy. Permeabilized cells were double stained with an E1 specific murine MAb A4, and with a rabbit antibody to calnexin as an ER marker. This was followed by staining of the cells with goat antimouse Ig-FITC for detection of E1 glycoprotein and antirabbit Ig-TRITC conjugate for detection of calnexin. Confocal microscopy suggested that E1 glycoprotein or its single glycosylation site mutants are expressed primarily on the cell surface as a clear green boundary above redstained ER (Fig. 4) . Interestingly, E1 glycoprotein gradually decreased its surface expression and localized in the ER with an increasing number of mutations at the glycosylation sites, as evident from the merge of green and red signals from confocal microscopy. The unglycosylated E1-G protein was also double stained with E1 specific A4 monoclonal antibody and with a rabbit antibody to giantin as a Golgi marker, and confocal microscopy suggested that the ungly- cosylated E1-G mutant fails to translocate to the Golgi (data not shown).
Mutation of E1-G glycosylation sites affects pseudotype virus titer
We examined whether VSV pseudotype generated from E1-G mutant retains infectivity. For this, pseudotype virus was generated by infecting BHK cells stably expressing E1-G or its N-linked glycosylation site mutants with VSVts045. Pseudotype titer was determined from the clarified culture supernatant in two different human epithelial cell lines (Huh-7 and MCF7), and in BHK cells for comparison (Fig. 5) . Culture supernatant from pcDNA3 vector transfected cells, infected with VSVts045, was included as a negative control. A higher pseudotype plaque titer with E1-G was apparent in both Huh-7 and MCF7, as compared to BHK cells. Pseudotypes generated from single or double mutants displayed plaque titers in each of the cell lines. Interestingly, virus plaque formation was reduced by approximately 5-fold upon mutation of E1-G at single glycosylation site (amino acid residue 196, 209, or 234) , which may be due to a decrease in expression level of the mutant E1-G on cell surface. On the other hand, approximately 2-fold reduction of pseudotype titers were observed following mutation of E1-G at amino acid residue 305, although the protein expression level was less compared to the other single mutations. This could be due to diminished functionality of E1-G for mutation at amino acid position 305. Mutations at two different glycosylation sites (amino acids Comparison of pseudotype titers generated from E1-G or its mutants at N-linked glycosylation sites. Three different cell types (Huh-7, MCF7, and BHK) were separately infected with pseudotype virus bearing E1-G or its mutants. Virus generated from pcDNA3 vector as a negative control was examined similarly for plaque formation. Plaque assay was done at 32 jC and virus titers (pfu/ml) are presented as mean value together with a standard deviation from at least three different experiments. Fig. 6 . N-glycosidase F treatment of pseudotype virus. Pseudotype generated from E1-G or its mutants and VSVts045 of known titer were treated with N-glycosidase F or left as untreated control for 24 h at 37 jC. Virus titer was determined by plaque assay in Huh-7 cells at 32 jC. The results are presented as the mean value together with standard deviations from at least three different experiments.
Together, these results suggested that pseudotype titer alters with a decrease in transport of E1-G on cell surface. However, mutation at amino acid residue 305 did not decrease virus titer to the same extent as observed with the other three mutants and the reason for this remains unclear at present.
N-glycosidase F treatment of pseudotype virus reduces infectivity
To understand whether enzymatic removal of preformed oligosaccharide side chains from the ectodomain of E1 protein would have an effect on infectivity, pseudotype virus generated from chimeric E1-G or its mutants were treated with N-glycosidase F. This enzyme treatment releases N-linked oligosaccharides from glycoproteins by hydrolyzing the glycosylated h-amide bond of an asparagine side chain. Denaturation of glycoprotein with detergent and heat before N-glycosidase F digestion increases the deglycosylation rate considerably; however, native protein can still be deglycosylated by increasing the incubation time to 24 h. As our aim was to determine infectious virus titer, pseudotypes (prior determined to contain 100 pfu in Huh-7 cells) were treated with N-glycosidase F in phosphate buffer, pH 7.5, in the absence of detergent or heat denaturation. A test protein, ribonuclease B, was included as a positive control for similar treatment. This positive control protein displayed >90% oligosaccharide digestion as determined by SDS-PAGE, followed by Coomassie blue staining (data not shown). E1-G pseudotype titer was reduced by approximately 35% upon treatment with N-glycosidase F, compared to mock-treated control. Similar results were also obtained even when pseudotype virus generated from single, double, or triple glycosylation site mutated clones were treated with N-glycosidase F (Fig. 6) . On the other hand, treatment of VSVts045 (as a negative control) with the enzyme did not significantly alter virus titer. These results suggested that removal of glycans present on mature E1-G reduced pseudotype titer to some extent, but was not able to completely inhibit virus infectivity.
HCV-infected human sera neutralize glycosidase-treated E1-G pseudotype
HCV E1 envelope glycoprotein is one of the targets for virus neutralizing antibodies. The ability of HCV to evade the immune system has been associated in part with both the variability of the envelope protein sequence and possibly by masking epitopes by glycosylation. Six HCV-infected human sera, previously identified as positive for E1 pseudotype neutralization , were tested at a 1:20 dilution for inhibition of infectivity of N-glycosidase Ftreated pseudotype virus (Table 1) . Sera from healthy donors at 1:20 dilution were also included as a negative control. All of these sera were also tested against the core virus (VSVts045) as a negative control. Three of these sera (A, B, and E) displayed an increase in plaque reduction, while serum D displayed a lower reactivity with enzyme-treated E1-G pseudotype virus. Two other sera (C and F) exhibited similar titer with N-glycosidase F-treated or untreated virus. On the other hand, sera from healthy donors (G and H) did not exhibit a significant neutralizing activity with the pseudotype virus or VSVts045 used as a negative control. Thus, the carbohydrate portion of the E1 glycoprotein did not appear to have a major significance in defining the neutralizing epitope(s).
Discussion
In this study, we have examined the role of glycans in the maturation and transport of HCV E1-G chimeric glycoprotein on to the mammalian cell surface, its similarities to fulllength E1, and its incorporation into pseudotype virus particles for the infectivity of mammalian cells. The oligosaccharide chains on the glycoproteins of many viruses play an important role in promoting the appropriate disulfide bond formation and folding that result in a fully functional glycoprotein. Little is known in terms of the relative contribution of the protein and carbohydrate to the various activities of HCV envelope glycoproteins. The role of the carbohydrate portion of E1 glycoprotein in other biological or immunological functions, such as attachment to cell surface, virus infectivity, and recognition by the host immune system, is now being studied. We have shown that both full-length E1 glycoprotein normally expressed in the ER and surface expressed chimeric E1-G glycoprotein are sensitive to Endo H treatment, indicating that the chimeric E1-G contains a high mannose glycosylation pattern similar to the full-length E1 glycoprotein. Translocation of E1-G protein to the cell surface is decreased to a different extent upon mutation of the number of glycosylation sites, and the recovery of pseudotype virus generated from these mutants also varies. N-glycosidase F treatment of the already synthesized E1-G glycoprotein reconstituted on a VSVts045 decreases pseudotype titer by approximately 35%. We also have shown that neutralization activity of patient sera is not significantly altered upon treatment of the pseudotype virus with N-glycosidase F. In the absence of a suitable cell culture system for an efficient HCV replication, our work highlights some of the interesting features of the E1 glycoprotein. This work will serve as a prelude to detailed investigations in determining the principal reactive group(s) of the E1 glycoprotein, and how this relates to its complex biological functions either alone or in association with E2 in intact HCV particles.
Conformational changes of some proteins are in some manner dependent upon glycosylation, whereas many proteins do not display glycosylation dependence during folding (Helenius and Aebi, 2001) . Additionally, glycans are not usually essential for maintaining the overall folded structure once a glycoprotein has folded (Helenius, 1994; Imperiali and O'Connor, 1999; Olden et al., 1982) . The biological role of the oligosaccharides in N-linked glycoconjugates is highly diverse. Carbohydrate markers are critical for intracellular targeting and intercellular recognition phenomena. Oligosaccharides on glycoproteins may play a role in protecting polypeptides from proteolytic attack and influencing the immunogenicity of the glycoproteins (Ellgaard et al., 1999; Means and Desrosiers, 2000; Trombetta and Helenius, 1998) . Mutation of the glycosylation sites of HCV E1 at amino acid positions 196, 209, and 234 does not effect the antibody titer induced in mice, whereas mutation at the fourth glycosylation site at position 305 significantly increases antibody response to E1 (Fournillier et al., 2001) . To investigate the antigenic determinants in partially or fully unglycosylated E1-G protein, N-glycosidase F-treated pseudotype virus was used for neutralization by a group of selected HCV patient sera. Interestingly, glycosidase treatment of pseudotype virus did not significantly alter the neutralizing activity of these sera. These results do not necessarily imply that carbohydrates play no role whatsoever in determining the immunological properties of E1 glycoprotein. Antibodies in patient sera were induced against fully glycosylated E1 glycoprotein during natural infection, and although they appear to react with nonglycosylated portions of the molecule, their specificity probably depends on molecular conformation, which could be influenced, at least to some degree, by the carbohydrate.
To examine the role played by N-linked carbohydrate chains in functional activity, we set out to investigate whether alterations in the glycosylation of E1-G would alter its function. Our results suggest that a single or double glycosylation mutation decreases the surface expression level as compared to fully glycosylated E1-G. However, E1-G expresses much less efficiently following mutations at three of the four glycosylation sites, while mutations at all four glycosylation sites lead to retention of the viral protein in the ER. We have shown previously that the pseudotype virus possibly enters into cells by receptor-mediated endocytosis, as an inhibitor of vacuolar H+ ATPases interferes with virus infectivity (Meyer et al., 2000) . The transmembrane domain of wild-type VSV G protein has been implicated for fusion activity. Replacement of glycine residues at positions 16 and 18 in the transmembrane domain with either alanine or leucine results in the complete loss of fusion activity (Cleverley and Lenard, 1998), while a single substitution at any of these positions decreases activity by half. Because our chimeric E1-G construct contains the G transmembrane domain and cytoplasmic tail from VSV, we examined whether the TM domain contributes to infection of E1-G pseudotype by mutations at positions 16 and 18. Our results indicated that these amino acid positions do not contribute to E1-G pseudotype infectivity (data not shown), as observed with VSV in context to its full-length G glycoprotein.
Information available from several other studies highlights the interesting features of HCV envelope glycoproteins. Recently, Bartosch et al. (2003a) presented data suggesting that MuLV/E1 or E2 pseudotype have the ability to independently infect cells, but to a much lower extent as compared to E1/E2 together. The authors suggested that high infectivity of the pseudotype particles required both E1 and E2 HCV glycoproteins. Pseudotypes with lentivirus bearing E1 and E2 have been shown to infect cells by other groups of investigators (Drummer et al., 2003; Hsu et al., 2003) . We also have observed an approximately 4-to 8-fold higher virus titer of VSV pseudotype generated from cell lines stably expressing both E1-G and E2-G in comparison to either of these two glycoproteins alone (unpublished observation). The transmembrane domains of E1 and E2 are involved in heteromerization by noncovalent interactions (Op De Beeck et al., 2000 Ralston et al., 1993) . However, we do not know at present whether this interaction imparts an effect on the structural relationship between the ectodomains of these two envelope proteins. It could be possible that both E1 and E2 associate through their transmembrane domains, while their ectodomains retain the ability to display independent functional activities. This is relevant with regard to the following interesting observations: (i) a truncated soluble form of E1 binds to CD81 and is conformation dependent (Flint et al., 1999) , while others have suggested that noncovalently linked E1E2 complex recognizes CD81 (Cocquerel et al., 2003) ; (ii) murine monoclonal antibodies that were characterized earlier as recognizing conformation-dependent epitopes of the E2 glycoprotein (Deleersnyder et al., 1997) react with E2 chimeric protein (Basu et al., 2004; Flint et al., 1999; Forns et al., 2000) ; (iii) a human MAb (CBH-2) has been characterized as recognizing E2 more efficiently only when it is complexed with E1 than E2 alone (Cocquerel et al., 2003; Hadlock et al., 2000) ; (iv) we consistently obtain infectivity from pseudotype virus bearing E1 or E2 as a single, chimeric envelope component (Basu et al., 2004; Lagging et al., 1998; Meyer et al., 2000 Meyer et al., , 2002 ; and (v) the human scavenger receptor class B type 1 (SR-B1), implicated as a HCV receptor, displays a strong affinity to E2 glycoprotein (Scarselli et al., 2002). However, HCV envelope (E1-E2)-derived lentivirus pseudotype particles were shown to require expression of CD81, LDL receptor, SR-B1, and liver-specific unknown cofactor(s) for infection (Bartosch et al., 2003b) . Although physicochemical and binding properties of the viral glycoproteins may not necessarily correlate with pseudotype infectivity, all of these interesting observations raise questions regarding the structural and functional differences of the E1 and E2 glycoprotein molecules alone or in association, and merit further investigation.
Taken together, we hypothesize that the heteromeric form of the associated E1 and E2 glycoproteins has exposed ectodomains through which they can display independent functional activities. The increase in infectivity titer with pseudotype bearing E1/E2 may be due to a synergistic effect for recognition of multiple receptors present on mammalian cells. Further studies are necessary for understanding the relationship between the ectodomains of E1 and E2, and their interplay with mammalian cells in facilitating virus entry.
Materials and methods

Cell lines and plasmids
Human cervical carcinoma cells (HeLa), baby hamster kidney cells (BHK-21), human breast cancer cells (MCF7), and human hepatoma cells (Huh-7) were grown and maintained in Dulbecco's medium supplemented with 10% fetal calf serum and antibiotics (100 U/ml penicillin and 100 Ag/ ml streptomycin).
Generation of plasmid containing chimeric E1-G gene under control of a cytomegalovirus (CMV) promoter has been described earlier (Lagging et al., 1998) . E1 has four conserved potential glycosylation sites at amino acids positions 196, 209, 234, and 305 . Site-direct mutagenesis at these four glycosylation sites on E1-G was performed by replacing asparagine with glutamine using a Quick Change Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA), following manufacturer's instruction. For each clone, sense and anti-sense primers were designed with the nucleotide change of the asparagine residues at the positions of interest (Table 2 ). Cloned DNAs were verified for altered nucleotides by automated sequencing (ABI prism).
Antibodies
Mouse monoclonal antibody A4, recognizing a linear epitope of E1 glycoprotein, was kindly provided by J. Dubuisson (Institut Pasteur de Lille Cedex, France). A different mouse monoclonal antibody recognizing linear epitope of E1 glycoprotein (Austral Biologicals, San Ramon, CA), rabbit antibodies to calnexin (Stressgen, Canada) and giantin (Covance Inc., CA), an anti-mouse immunoglobulin-FITC conjugate and anti-rabbit immunoglobulin-TRITC conjugate (Molecular Probes, Eugene, OR) were purchased.
Metabolic labeling and immunoprecipitation
HeLa cells were infected with a recombinant vaccinia virus expressing T7 polymerase (vvT7) at a multiplicity of infection (moi) of 2 and transfected with plasmid DNA encoding full-length E1, chimeric E1-G or E1-G mutants. Cells were metabolically labeled with 200 ACi/ml 35 Scysteine/methionine protein labeling mix as described previously (Ray et al., 1994) . Cells were lysed after 18 h of transfection, and E1 was immunoprecipitated with either MAb A4 or a commercially available MAb to E1 (Austral Biologicals).
Endoglycosidase H digestion
Immunoprecipitated proteins were eluted from protein GSepharose in 25 Al buffer (100 mM phosphate buffer, pH 5.5, 0.2% SDS, and 1% h-mercaptoethanol) by boiling for 10 min. Samples were digested with Endoglycosidase H (Endo H; Calbiochem, La Jolla, CA) or left untreated as a negative control for 24 h at 37 jC. Samples were mixed with an equal volume of 2Â sample reducing buffer. Samples were analyzed by SDS-PAGE, followed by autoradiography.
Western blotting
HeLa cells were infected with vvT7 at a moi of 2 and transfected with plasmid DNA encoding chimeric E1-G, full-length E1, or pcDNA3 vector as a negative control. Table 2 Oligonucleotide primers used to mutate E1-G glycosylation sites
Mutation sites
Primer sequences a N196Q sense primer: 5V-GCCTACCAAGTGCGCCAATCCACGGGGCTTTAC-3V antisense primer: 5V-GTAAAGCCCCGTGGATTGGCGCACTTGGTAGGC-3V N209Q sense primer: 5V-CCAATGATTGCCCTCAATCGAGTATTGTGTAC-3V antisense primer: 5V-GTACACAATACTCGATTGAGGGCAATCATTGG-3V N234Q sense primer: 5V-GCGTTCGTGAGGGCCAAGCCTCGAGGTGTTGG-3V antisense primer: 5V-CCAACACCTCGAGGCTTGGCCCTCACGAACGC-3V N305Q sense primer: 5V-CGACGCAAGGTTGCCAATGCTCTATCTATCCC-3V antisense primer: 5V-GGGATAGATAGAGCATTGGCAACCTTGCGTCG-3V a Underlined nucleotides indicate the mutations introduced in the E1-G sequence to alter potential glycosylation sites.
Transiently transfected cells were lysed after 18 h and E1 protein was immunoprecipitated using a specific murine Mab (Austral Biologicals). Immunoprecipitates were digested with Endo H or left untreated as a negative control for 24 h at 37 jC. Samples were separated by SDS -12% polyacrylamide gel electrophoresis, and the proteins were transferred onto nitrocellulose membrane. HCV E1 protein was detected with mouse MAb A4 and anti-mouse immunoglobulin conjugated to peroxidase. The peroxidase signal was visualized by chemiluminescence.
N-glycosidase F treatment
Pseudotype virus generated from chimeric E1-G or its mutants of known titer was treated with or without Nglycosidase F (Calbiochem) as a control for 24 h at 37 jC in phosphate buffer, pH 7.5, as recommended by the manufacturer. Denaturation of glycoprotein with detergent and heat before N-glycosidase F digestion increases the deglycosylation rate considerably; however, native protein can still be deglycosylated by increasing the incubation time to 24 h. We also tested the efficacy of N-glycosidase F treatment using ribonuclease B (protein containing high mannose) as a positive control under similar experimental conditions as pseudotype virus was treated. Comparison between untreated and treated samples displayed >90% oligosaccharide digestion of ribonuclease B, as determined by densitometric scanning (SynGene Gel Documentation System, UK) of Coomassie blue-stained gel.
Immunofluorescence and confocal microscopy
HeLa cells grown on coverslips were infected with vvT7 at a moi of 2 and transfected with plasmid DNA encoding E1 glycoprotein using lipofectamine (Invitrogen, Carlsbad, CA) following the manufacturer's protocol. At 18 h posttransfection, cells were left either unfixed or were fixed in 10% formaldehyde for 20 min at room temperature. Cells were treated with anti-E1 MAb A4 and a rabbit antiserum to calnexin as an ER marker or anti-giantin as a Golgi marker. Secondary antibody conjugated to fluorochrome was added subsequently. Cells on coverslips were fixed after staining and mounted on microscope slides in antifade reagent (Molecular Probes) for microscopy using a Zeiss Axiovert 135 or a BioRad 1024 confocal microscope.
Pseudotype generation using single or multiple mutations on E1G glycosylation site Incorporation of HCV E1-G chimeric glycoprotein into a temperature-sensitive mutant of VSV (VSVts045) has been previously described for understanding the functional properties of the ectodomain of HCV E1 glycoprotein . VSVts045 has a G protein with a single amino acid change in the ectodomain and a thermoreversible folding phenotype (Doms et al., 1993) . At nonpermissive temperature (40.5 jC), G protein of VSVts045 is synthesized and core glycosylated normally, but does not fold correctly. However, the temperature-sensitive mutant virus does not tightly regulate this process and the possibility for leakage of G cannot be ruled out. To safeguard this, we have used a stock of VSVts045 selected after four rounds of plaque purification, which did not exhibit any significant background virus leakage at 40.5 jC. The plaque purified VSVts045 virus stock was used for the generation of VSV/ HCV pseudotype by infecting BHK stable transfectants expressing E1-G or mutant protein. Cells transfected with an empty vector were similarly treated with VSVts045 as a negative control. Wild-type VSV G (VSV G wt ) cloned into pcDNA3 under the control of a T7 promoter was also used as a positive control for generation of pseudotype virus (Lagging et al., 1998) . The culture fluid was flash frozen in aliquots, and each aliquot was thawed only once for use in a single round of virus replication by plaque assay for VSVts045 at a permissive temperature (32 jC). The pseudotype virus showed titers in the order of approximately 10 4 pfu/ml in BHK cells, while mock-transfected negative control displayed less than 1% of virus titer, and G wt /VSV displayed a titer of approximately 10 5 pfu/ml. Treatment of pseudotype virus with an antiserum to VSV G did not significantly alter virus titer, suggesting the absence of revertant VSV G in the virus preparation. The pseudotype virus from E1-G was neutralized by known HCV-infected patient sera , and none of these sera at similar dilutions exhibited a significant neutralization titer (<20%) for VSVts045 when tested as a negative control. Sera from healthy adults also displayed neutralization titer of (<10%) of E1-G or VSVts045 virus infectivity. These results further suggested the versatility of parental VSVts045 for recognition, and entry into mammalian cells, and the relative constraints placed upon VSV pseudotype virus expressing the E1-G glycoprotein. On the other hand, antibody to VSV-G efficiently neutralized VSV-G pseudotype virus.
Neutralization assay of deglycosylated pseudotype virus by HCV-infected human sera
Infectivity of the E1 pseudotype virus depends upon the interaction of HCV glycoproteins with target cells (Lagging et al., 1998) . Once the VSVts045 genome enters after interaction of E1 with the cell surface, normal replication of VSVts045 occurs at permissive temperature (32 jC), and virus plaques are detected. Pseudotype virus generated from E1-G or its mutants of known titer was treated with Nglycosidase F (Calbiochem) or left as untreated control for 24 h at 37 jC in phosphate buffer, pH 7.5. A plaque assay for virus infectivity and its neutralization by antibodies were determined in mammalian cells at 32 jC in a serum-free medium (Meyer et al., 2000 . Pseudotype virus of a known titer was incubated with HCV-infected human sera or sera from healthy donors as negative control at 32 jC for 1 h. Cells incubated with virus -antibody mixture for 1 h with intermittent tilting. Cells were washed and overlaid with 0.8% agarose in DMEM, containing 2% fetal bovine serum. Virus plaques were read after 24 -48 h of incubation at 32 jC in a 5% CO 2 incubator.
